Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 3.17 is 69% below its 5-year average of 10.27, near the low end of its 5-year range (3.17–21.36).
As of the fiscal period ended Tuesday, June 30, 2026. 21.36% below its 12-month average of 4.03.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.17.
QUICK RATIO (ACID-TEST)
3.17
QUICK RATIO (ACID-TEST) AVG TTM
4.03
QUICK RATIO (ACID-TEST) AVG 3Y
5.20
QUICK RATIO (ACID-TEST) AVG 5Y
10.27
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-21.36%
CURRENT VS 3Y AVG
-39.03%
CURRENT VS 5Y AVG
-69.11%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
-5.29%
vs the sector median at left
Tarsus Pharmaceuticals, Inc.
Market Cap
$3.20B
Quick Ratio (Acid-Test)
3.17
TTM Avg
4.03
3Y Avg
5.20
5Y Avg
10.27
Market Cap
$3.12B
Quick Ratio (Acid-Test)
12.12
TTM Avg
10.47
3Y Avg
8.53
5Y Avg
7.00
Market Cap
$3.31B
Quick Ratio (Acid-Test)
4.72
TTM Avg
21.21
3Y Avg
17.30
5Y Avg
19.05
Market Cap
$3.06B
Quick Ratio (Acid-Test)
8.32
TTM Avg
8.81
3Y Avg
8.76
5Y Avg
9.71
Market Cap
$3.03B
Quick Ratio (Acid-Test)
64.07
TTM Avg
24.32
3Y Avg
16.73
5Y Avg
16.77
Market Cap
$3.38B
Quick Ratio (Acid-Test)
3.30
TTM Avg
3.01
3Y Avg
3.08
5Y Avg
4.22
Market Cap
$3.36B
Quick Ratio (Acid-Test)
17.91
TTM Avg
1.68
3Y Avg
1.68
5Y Avg
1.68
Market Cap
$2.99B
Quick Ratio (Acid-Test)
2.67
TTM Avg
3.48
3Y Avg
6.28
5Y Avg
8.36
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.20B | 3.17 | 4.03 | 5.20 | 10.27 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | 12.12 | 10.47 | 8.53 | 7.00 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | 4.72 | 21.21 | 17.30 | 19.05 |
| CareDx, Inc (CDNA)vs › | $3.30B | 4.51 | 3.14 | 3.73 | 4.01 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | 8.32 | 8.81 | 8.76 | 9.71 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | 64.07 | 24.32 | 16.73 | 16.77 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 3.30 | 3.01 | 3.08 | 4.22 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 17.91 | 1.68 | 1.68 | 1.68 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 2.67 | 3.48 | 6.28 | 8.36 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 9.61 | 11.20 | 9.88 | 7.68 |
Quick Ratio
3.17
Excludes inventory
Current Ratio
3.20
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 3.17 |
| 2026-03-31 | 3.71 |
| 2025-12-31 | 3.82 |
| 2025-09-30 | 4.25 |
| 2025-06-30 | 5.21 |
| 2025-03-31 | 5.54 |
| 2024-12-31 | 4.39 |
| 2024-09-30 | 5.38 |
| 2024-06-30 | 6.99 |
| 2024-03-31 | 7.92 |
| 2023-12-31 | 6.85 |
| 2023-09-30 | 11.15 |
| 2023-06-30 | 12.43 |
| 2023-03-31 | 15.74 |
| 2022-12-31 | 14.61 |
| 2022-09-30 | 16.40 |
| 2022-06-30 | 21.36 |
| 2022-03-31 | 14.18 |
| 2021-12-31 | 15.33 |
| 2021-09-30 | 18.05 |
| 2021-06-30 | 19.22 |
| 2021-03-31 | 18.92 |
| 2020-12-31 | 31.68 |
| 2020-09-30 | 14.50 |
| 2020-06-30 | 17.79 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 70.85 |
| 2019-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
